Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 4:37 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 37 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo for Upadacitinib Clear all

Conditions: Rheumatoid Arthritis
Interventions: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 487 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 85
States / cities: Flagstaff, Arizona • Glendale, Arizona • Peoria, Arizona + 75 more

Conditions: Vitiligo
Interventions: Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy; Drug · Other
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 614 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 46
States / cities: Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more

Conditions: Ulcerative Colitis Acute
Interventions: Oral Upadacitinib, Intravenous Methylprednisolone, Oral Upadacitinib Placebo, Oral prednisolone Taper, Oral Prednisone - Hospital Dose Steroids; Drug
Lead sponsor: Berinstein, Jeffrey; Other
Eligibility: 18 Years to 75 Years
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Alopecia Areata
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years to 63 Years
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 78
States / cities: Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 63 more

Conditions: Ulcerative Colitis (UC)
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 522 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 114
States / cities: Mobile, Alabama • Sun City, Arizona • Tempe, Arizona + 90 more

Conditions: Rheumatoid Arthritis (RA)
Interventions: Abatacept, Placebo for abatacept (0.9% Sodium Chloride Injection or Solution for Infusion), Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 657 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 44
States / cities: Peoria, Arizona • Sun City, Arizona • Tucson, Arizona + 40 more

Conditions: Psoriatic Arthritis
Interventions: Adalimumab, Upadacitinib, Placebo to Upadacitinib, Placebo to Adalimumab; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 1,705 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 114
States / cities: Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 100 more

Conditions: Long COVID
Interventions: Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib; Drug
Lead sponsor: Douglas D. Fraser; Other
Eligibility: 18 Years to 65 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Elsubrutinib, Placebo for Elsubrutinib, Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 21
States / cities: Phoenix, Arizona • Beverly Hills, California • Los Alamitos, California + 18 more

Conditions: EoE, Eosinophilic Esophagitis, Eosinophilic Esophagitis (EoE)
Interventions: Upadacitinib 30mg Dose, Upadacitinib Matching Placebo; Drug · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Durham, North Carolina

Conditions: JAK1 GOF, STAT1 GOF, STAT3 GOF, STAT5B GOF, STAT6 GOF
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: Lisa Satter; Other
Eligibility: 12 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: St Louis, Missouri • New York, New York • Houston, Texas

Conditions: Rheumatoid Arthritis
Interventions: Methotrexate, Upadacitinib, Placebo Upadacitinib, Placebo Methotrexate; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 648 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 52
States / cities: Huntsville, Alabama • Mobile, Alabama • Gilbert, Arizona + 43 more

Conditions: Psoriatic Arthritis, Spondyloarthritis, Axial
Interventions: Upadacitinib 15 MG [Rinvoq], Placebo; Drug
Lead sponsor: CARE ARTHRITIS LTD.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 3
States / cities: Cleveland, Ohio • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: Hemet, California • DeBary, Florida • Venice, Florida + 9 more

Conditions: Myositis Associated Interstitial Lund Disease (MA-ILD)
Interventions: Nintedanib, Placebo, Standard of Care; Drug
Lead sponsor: Rohit Aggarwal, MD; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more

Conditions: Hidradenitis Suppurativa
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 12 Years and older
Enrollment: 1,328 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 73 more

Conditions: Non-Segmental Vitiligo
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 20
States / cities: Irvine, California • Redwood City, California • Boca Raton, Florida + 16 more

Conditions: Crohn's Disease
Interventions: Upadacitinib, Placebo for Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 747 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 123
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 97 more

Conditions: Ulcerative Colitis (UC)
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 16 Years to 75 Years
Enrollment: 1,302 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2021
U.S. locations: 149
States / cities: Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 114 more

Conditions: Atopic Dermatitis
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 10
States / cities: Tampa, Florida • Sandy Springs, Georgia • Rockville, Maryland + 7 more

Conditions: Crohn's Disease
Interventions: Vedolizumab, Upadacitinib, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 19
States / cities: La Jolla, California • Los Angeles, California • Colorado Springs, Colorado + 12 more

Conditions: Systemic Lupus Erythematosus
Interventions: Upadacitinib, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 63 Years
Enrollment: 1,014 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 132
States / cities: Chandler, Arizona • Flagstaff, Arizona • Gilbert, Arizona + 107 more

Conditions: Rheumatoid Arthritis
Interventions: Placebo, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 661 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 57
States / cities: Mesa, Arizona • Peoria, Arizona • Phoenix, Arizona + 49 more

Conditions: Crohn's Disease
Interventions: Matching Placebo for Upadacitinib, Upadacitinib; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 119
States / cities: Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 92 more

Search by objective public record fields.

Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

Upadacitinib Combined With Corticosteroids vs Corticosteroid Monotherapy Induction for Inpatients and Outpatients With Acute Severe Ulcerative Colitis

A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Ulcerative Colitis

A Phase 3 Study to Compare Upadacitinib to Abatacept in Subjects With Rheumatoid Arthritis on Stable Dose of Conventional Synthetic Disease- Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response or Intolerance to Biologic DMARDs

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD)

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

A Study of the Safety of Oral Elsubrutinib Capsules and Oral Upadacitinib Tablets Given Alone or in Combination (ABBV-599) for Adult Participants With Moderately to Severely Active Systemic Lupus Erythematosus to Assess Change in Disease State

A Trial of Upadacitinib for Non-responsive Eosinophilic Esophagitis

Upadacitinib in Treatment of JAK/STAT Pathway Disorders With Activating Mutations

A Study Comparing Upadacitinib (ABT-494) Monotherapy to Methotrexate (MTX) Monotherapy in Adults With Rheumatoid Arthritis (RA) Who Have an Inadequate Response to MTX (SELECT-MONOTHERAPY)

A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis

A Study Investigating the Efficacy and Safety of Upadacitinib (ABT-494) Given With Methotrexate (MTX) in Adults With Rheumatoid Arthritis Who Have Had an Inadequate Response to MTX Alone

Myositis Interstitial Lung Disease Nintedanib Trial

A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy

Study to Evaluate Adverse Events and Change in Disease Activity With Oral Tablets of Upadacitinib in Adult Participants With Non-Segmental Vitiligo

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

A Study to Evaluate the Safety and Efficacy of Upadacitinib (ABT-494) for Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

A Study to Evaluate ABT-494 (Upadacitinib) in Adults With Moderate to Severe Atopic Dermatitis

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus

A Study Comparing Upadacitinib (ABT-494) to Placebo in Adults With Rheumatoid Arthritis on a Stable Dose of Conventional Synthetic Disease-Modifying Antirheumatic Drugs (csDMARDs) Who Have an Inadequate Response to csDMARDs Alone

A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy